Pfizer starts late-stage clinical trials Lyme disease vaccine

A new Lyme disease could be available in the U.S. as early as 2025, as Pfizer has launched final clinical trials for its jab, VLA15. The company is aiming to apply for FDA approval in 2025.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news